« Back to Farmacia Journal 2/2021

PIPERACILLIN COMBINED WITH AZITHROMYCIN IN THE TREATMENT OF CHILDHOOD MYCOPLASMA PNEUMONIAE PNEUMONIA AND THE INFLUENCE ON THE INTESTINAL MICROECOLOGY

NA QIN ¹, GUOYAN YIN ¹, LIJUAN CHEN ¹, NAN PING ¹, SIHUI ZHAO ¹, HUIBIN QIN ^2*

Download Full Article PDF

This study aimed to investigate the clinical effect of piperacillin combined with azithromycin in the treatment of childhood Mycoplasma pneumoniae pneumonia (CMP). Forty-eight children patients with Mycoplasma pneumoniae pneumonia were divided into two groups: a control group and an experimental group, according to the random number table method. Children patients in the control group were treated with 10 mg/kg bw/day azithromycin by intravenous drip for three consecutive days, and then 5 mg/kg bw/day azithromycin orally for 4 days. The patients in the treatment group received 143 mg/kg bw/day piperacillin intravenously for 1 week combined with the same regiment of azithromycin as in the control group. The therapeutic effect, defervescence time, disappearance time of cough, disappearance time of lung sound, absorption time of chest radiograph, lung function indexes and related inflammatory factors before and after treatment, intestinal microecology, and drug adverse reaction rate were compared among children patients in the two groups. Piperacillin combined with azithromycin in the treatment of CMP greatly improved the clinical symptoms and lung function and reduced the levels of inflammatory factors, leading to mild adverse reactions compared with the treatment with azithromycin alone. However, the effect of combined treatment on the destruction of intestinal microecological balance was higher compared with the treatment with azithromycin alone.